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A microbiologic technique for the assay of methotrexate (MTX) in urine, serum, 
erythrocytes, feces, and skin is described. The accuracy of the method equals that of routine 
microbiologic assays of folic acid. Important differences in serum MTX levels in psoriatic 
patients during the 24 hr after standardized intravenous and intramuscular administration 
were demonstrated, Repeated intravenous doses tended to be cleared from the blood 
uniformly, 
After oral doses many patients achieved peak serum levels within 2 hr, with fall of level by 
4 hr, Others achieved lower levels and responded less well clinically. Persistence of high 
serum levels at 24 and 48 hr did not confer obvious clinical benefit or necessarily give rise to 
toxicity, The pattern of clearance from serum was not influenced by serum albumin levels or 
by renal function when the creatinine clearance was greater than 50 ml/min, However, 
impaired renal function was clearly correlated with slow clearance. 
Routine measurement of MTX blood levels is of value in patients with suspected 
malabsorption or partial renal failure, 
Methotrexate (MTX) remains unchallenged as 
the most effective systemic drug available for the 
management of certain categories of severe psoria-
sis unresponsive to topical therapy [1,2]. However, 
dosage schedules remain empirical, based on the 
clinical response and clinical or laboratory evi-
dence of toxicity. 
Patients might be expected to metabolize a drug 
in different ways, leading to varying blood, urine, 
and tissue levels. The safety margin between 
effective and toxic doses is often small and there is 
no routinely available method for detecting accu-
mulation of the drug in the tissues. A study of the 
absorption and excretion of MTX might enable us 
to understand some of these variations, With this 
in mind, we have investigated the fate of MTX 
prescribed to psoriatic patients, 
There are several methods available for estimat-
ing MTX levels, including fluorometric analysis 
[3), inhibition of folic acid reductase [4), and use of 
tritium-labeled MTX [5 J. However, for routine 
estimation (on potentially large numbers of pa-
tients) the microbiologic method of Burchenal and 
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his colleagues [6 J seemed to be the most satisfac-
tory, and the assay method was adapted from their 
work. 
MATERIALS AND METHODS 
Assay Procedure 
Difco folic acid assay (FAA) medium was made up as 
follows: 
FAA 
Oxoid agar no, 3 
Folic acid (Analar) 
37,5 gm/liter 
12 gmll iter 
10 ngiliter 
The medium was autoc!aved at 15 Ib (l21°C) for 15 
min and allowed to cool at 42'C, 
Cultures of a folic acid-dependent organism were 
added to the cooled medium and "pour" plates were 
made on the assay day in 9-cm Petri dishes at 20 
ml/plate, Cultures of Streptococcus faecalis NCIB 6459, 
NCIB 8123. NCIB 8966, and Lactobacillus casei var. 
rhamnosus NCIB 6395 and NCIB &lIO were maintained 
lyphophilized or, for short periods, in maintenance me-
dium, Subcultures were made on blood agar to check 
purity, and nutrient broth cultures were made from the 
blood agar, Overnight broth cultures were added to the 
molten FAA agar at II concentration of 1 ml/liter. After 
the plates had set they were dried for 1 hr at 37°C, A hole 
2 mm in diameter was punched in the center of the plate 
and filled with the fluid under assay. 
A diffusion period of about 30 min was allowed 
(although serum diffused very little in this time), Plates 
were then incubated aerobically-streptococcus plates 
for 18 hr and lactobacillus plates for 36 hr, at 37"C. The 
diameter of the zone of inhibition surrounding the holes 
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was measured to the nearest millimeter. All cultures were 
found to give good assay, and zone diameters were in 
proportion to known amounts of MTX. However, lacto-
bacillus cultures gave larger zones for given quantity of 
drug, making measurement easier, and all assays re-
ported here were made with NCIB 8010. 
Preparation of Specimens 
Blood. The time of venepuncture was noted. The cells 
were removed by centrifugation to leave serum which was 
normally assayed unautoclaved. (Autoclaving had no 
significant effect; 13 specimens were assayed in parallel, 
mean zone diameter unautoclaved 39.6 mm, autoclaved 
38.6 mm, SD ~ 1.8 mm.) Red cells were washed three 
times with saline and lysed in distilled water made to the 
same volume as the original blood specimen. This mate-
rial is referred to as "red cell Ivsate." 
Urine. The time of voiding ~nd the total volume were 
noted. A 25-ml sample of urine was autoclaved and stored 
at -20°C prior to assay. Autoclaving proved necessary to 
prevent urinary-tract contaminants from overgrowing the 
assay plates. (There was no apparent effect on the level of 
MTX assayed; 74 specimens were assayed in parallel, 
mean zone diameter 43.3 mm unautoclaved, 43.7 auto· 
claved, SD ~ 1.9 mm.) 
Tissue. Pieces of tissue, squamous epithelial debris, or 
liver biopsies, were examined. (Liver hiopsies were taken 
for histologic examination for evidence of hepatotoxicity. 
Material examined for MTX was that in excess of 
histologic requirement and was received prior to fixa-
tion.) In skin it was found that autoclaving at 121°C in 
phosphate buffer, pH 8.4, gave the greatest recovery. 
Liver biopsies were too small to allow a range of condi-
tions to be tried; they were therefore extracted under the 
optimum conditions found for skin. All specimens were 
stored at - 20 D C prior to assay. 
Homogenized fecal samples of approximately 100 gm 
were dialyzed against water for 24 hr and the dialysate 
concentrated to approximately 5 m!. 
Clinical Material 
Many of the 82 patients contrihuting to this study were 
inpatients at The London Hospital or at St. John's 
Hospital for Diseases of the Skin. Others were outpa· 
tients attending Psoriasis Clinics run by one of us (H.B.) 
at the two hospitals. Before MTX was given, the follow-
ing tests were completed in addition to an ordinary 
clinical assessment: full hlood count; urinalysis, includ-
ing hlood urea and creatinine clearance tests; liver 
-function tests, including bromsulfphthalein (BSP) re-
tention and liver biopsy in many patients; and chest 
radiograph. 
Standard MTX doses of 0.22 mg/kilo were generally 
used when blood sampling was intended. Small test doses 
were given to patients with impaired renal function. 
RESULTS 
Standardization of Assay 
To construct the initial correlation curve, 
weighed amounts of MTX were added to distilled 
water, suitable dilutions prepared, and the inhibi-
tion-wne diameter measured. Separate curves ob-
tained using pure MTX (from Lederle Ltd.) and 
commercial vials containing 5 mg or 50 mg of MTX 
and varying amounts of parabens and sodium 
chloride did not differ significantly. In the final 
analysis a composite curve, derived from the pure 
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FIG. 1. Correlation curve with 95% confidence limits 
between inhibition-zone diameter and quantity of metho· 
trexate. 
MTX and 50-mg commercial vials, was used and 
checked for validity against data from 5-mg vials. 
The final correlation curve is shown in Figure 1; it 
is based on 328 observations (correlation coeffi-
cient, 0.99; residual SD, 2.5 mm; mean-zone diam-
eter, 50.9 mm). The standard deviation is 5o/r: of the 
mean reading, which is comparable with the reo 
suits for assay of folic acid [7]. 
Validity of Assay 
Attempts to validate the assay were important 
in view of the results obtained with specimens from 
patients. Since assay of 5-mg commercial vials 
dissolved in distilled water, human serum, or 
normal urine gave results exceptionally close to 
those of the standard curve, the assay was judged 
to be valid for laboratory specimens. Clinical 
specimens assayed in duplicate on the same day 
gave results which were very close with a small 
standard deviation (68 pairs, mean (a) ~ 35.5 mm, 
(b) = 35.8 mm, SD ~ 1.9 mm). Assays repeated 1 
week later were also close, although, as expected, 
the standard deviation was greater (24 pairs, mean 
week 1 ~ 40.8 mm, mean week 2 ~ 40.5 mm. SD = 
3.7 mm). 
Stability of Drug in Solution 
Solutions in distilled water showed no loss of 
potency over a period of 1 month when stored in 
the dark at 4°,25°, and 37°C. Specimens stored in 
the light at 25° and 37~C lost 50% of potency in 1 
month. 
Influence of Natural Folate Levels 
Neither normal human urine (12 individuals) 
nor normal serum (37 individuals) contained any 
substance which inhibited the growth of L. casei. 
There remained the possibility, however, that the 
normal folate levels of the specimen might inter-
fere in the test. Burchenal et al [6] used higher 
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10ses of folic acid in their medium without in-
.. alidating the assay. This was confirmed in the 
Jresent series by raising the quantity of folic acid 
.dded to the FAA medium by lO-fold. Two alterna-
tive methods were used to further clarify this point. 
Samples of distilled water to which both MTX and 
folic acid had been added in a checkerboard 
pattern were assayed; a ratio of folic acid to MTX 
of 500:1 was required to eliminate the zone of 
inhibition in the assay. In addition, high levels of 
serum folate were induced in humans by the 
introduction of excess folic acid or folinic acid by 
the oral or intramuscular route. (Serum levels 
achieved by tbe oral route were 6.3 to 35.9 ng/ml 
[mean 24.2 ng/ml] and 162 to 560 ng/ml [mean 432 
ng/ml] by the intramuscular route in 15 non· 
psoriatic patients.) None of these levels interfered 
with the assay of MTX added in vitro. 
Protein Binding 
Although the degree of protein binding was not 
directly investigated, it appears likely that bound 
material was released during the assay. Autoclav· 
ing of serum from patients with therapeutic MTX 
levels failed to reveal any increase in level (see 
above). About 50% of serum folic acid is bound and 
can be released by autoc\aving [7J. 
Red cell lysates (RCL) were found to contain 
MTX in the absence of detectable serum levels. 
This MTX was presumably in a bound or intracel-
lular form prior to assay. No binding could be 
demonstrated when MTX was added to human 
serum, horse serum, human urine, or distilled 
water. 
Assay of Clinical Material 
Over 9(){){) assays on clinical material were per· 
formed. It was possible to detect MTX in concen· 
trations as low as 0.5 ng/ml, but below 4 ng/ml the 
assay was quantitatively less reliable. The peak 
level measurable was 23,000 ng/ml, corresponding 
to a 70·mm inhibition zone. Above this level 
nonstoiciometric results were obtained and speci. 
mens were diluted 1:10 for assay. 
Urine [euels. Recovery of MTX from the urine 
showed that about 90% of the drug excreted by this 
route appeared in the first 24 hr, although most 
patients still had detectable levels in the urine 2 t.o 
3 weeks after a dose. Assuming a normal urinary 
concentration factor, the blood levels required to 
produce these low urine levels would be below the 
limit of detection. 
Using the product of total urine volume voided 
and the level of drug assayed, it was possible to 
compute the total urinary excretion. This was 
considerably less than the dose administered. Indi-
vidual patients were fairly consistent in the propor-
tion of drug excreted by the urinary route after 
repeated doses. 
Feces. Excretion via the bile was investigated by 
sampling feces from patients given intramuscular 
MTX. MTX was detected in 6 of 7 samples from 3 
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individuals in amounts varying from 25 ng/gm to 
1000 ng/gm. This method was not practicable for 
routine assay but suggests a route via which some 
or much drug may have been excreted. 
Tissue. Samples of skin obtained 3 or 4 days 
after a routine weekly dose of MTX were assayed 
from 5 individuals. Epidermis from psoriatic 
plaques of 1 patient and normal epidermis from 
another failed to yield an inhibitory zone. Both 
normal and psoriatic epidermis from the others 
gave levels between 200 and 400 ng/mg. 
Liver biopsies were obtained shortly before a 
standard weekly dose of MTX from 12 patients; all 
were negative for MTX. One further specimen 
which proved positive was taken within 3 hr after 
administration of the drug and probably reflects 
the blood level. 
Assay of Therapeutic Material 
During the course of the investigation it became 
desirable to determine whether there was any gross 
variation between different batches of tablets sup-
plied for therapeutic use. Accordingly, 8 tablets 
with different batch numbers were dissolved in 
distilled water and assayed. At about 250 ng/ml 
the tablets assayed gave zone diameters between 
43 and 51 mm, mean 47.6 mm. The standard curve 
read 47.5 mm at this point with 95% confidence 
limits of 42.5 and 52.5 mm. 
Clearance of Single Intravenous Doses 
The initial level was usually measured by sam-
pling venous blood from the arm opposite to that 
used for the intravenous injection, 90 sec after 
administration of the drug. Further samples were 
collected at intervals. With 0.22 mglkilo doses, 
serum levels up to 10,000 ng/ml were present after 
90 sec. Falloff was apparent within 10 min and 
progressive over 24 hr; a typical pattern is shown in 
Figure 2. Up to I5-fold differences were observed 
between levels found in different patients at 1 and 
6 hr and up to 30-fold differences were seen at 24 hr 
(Fig. 3). These variations could not be correlated 
with serum albumin levels. There was no correla-
tion between red-cell uptake of MTX and rapidity 
of clearance of the drug from the serum. 
In 3 patients given 0.44 mg/kilo of MTX, serum 
levels were no higher than with the smaller dose at 
6 hr and thereafter. This suggests that the initial 
high levels seen for up to 1 hr were cleared very 
rapidly, presumably into the tissues and excreted 
by the kidneys and liver. Such single doses only 
rarely seriously disturbed the patient. One woman 
(twice given 0.22 mg/kilo) developed hallucina-
tions which ceased promptly when MTX was 
withdrawn. There was nothing atypical about her 
serum levels after each dose. Several patients 
complained of variable nausea within 12 hr of an 
intravenous dose but there was no correlation 
between presence of nausea and blood levels of the 
drug. One 73-year-old woman developed inflam-
mation, "burning" skin, pain, and erosion of pso· 
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FIG. 2. Serum methotrexate levels after an intrave-
nous dose. 
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FIG. 3. Serum methotrexate levels after single intra-
venous doses (32 patients). 
ria tic plaques 36 to 48 hr after a single intravenous 
dose of 0.5 mg/kilo. These findings were associated 
with high persisting MTX levels. Serum MTX was 
500 ng/ml after 24 hr, and 16 ng/mi were still 
detectable in the serum after 6 days. Single doses 
higher than 0.44 mg/kilo have not subsequently 
been used. Repeated measurements were made 
after identical doses in some of these patients at 
weekly or greater intervals. Figures 4 and 5 show 
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that such repeated doses were cleared rather uni-
formly with only minor variations in the measured 
serum levels. This suggests that the interpatient 
variation is reaL 
Clearance of Single Intramuscular Doses 
Single intramuscular doses of MTX were cleared 
from the serum more slowly than intravenous 
doses; the findings are summarized in Figure 6 
which shows the considerable variations in levels 
for up to 24 hr after standard doses. These patients 
include 3 in whom use of maintenance MTX was 
unavoidable, although renal function was known 
not be normaL 
Initial levels are lower but high levels are often 
maintained for several hours longer, perhaps be-
cause of delayed release from the infection site. 
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FIG. 4. Consistent handling of intravenous doses of 
methotrexate. X and. represent 2 patients. 
MTX/ml 
500 
9 10 II 1.2 
FIG. 5. Consistent handling of two intramuscular 
doses of methotrexate by 1 patient. The solid line 
represents the serum level and the broken line the 
red-cell lysate leveL 
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FIG. 6. Serum methotrexate levels after single intra-
muscular doses (12 patients). 
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FIG. 7. Serum methotrexate levels after single oral 
doses (44 patients). 
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FIG. 8. Comparison of serum methotrexate levels in 
patients with comparable psoriasis who had a "good" (0) 
or a "poor" (e) response tc the drug. 
Two distinct patterns were seen in these patients. 
In some, high initial levels fell rapidly to 300 nglml 
or less within 6 hr and to 20 nglml or less within 12 
hr. In others, initial levels were uniformly lower 
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but persistent, 4-hr levels being comparable with 
those in patients with high initial levels. Three of 
these latter patients had persistent high levels at 
12 and 24 hr; they showed an excellent clinical 
response but mild clinical toxicity. All 3 had some 
impairment of renal function with mild cardiac 
failure, which might explain the persistent high 
levels but not the initial low ones. The 2 patients 
with the highest 12-hr levels both suffered from 
troublesome headaches for a day after the injec-
tion, a symptom found in a minority of patients on 
intramuscular therapy. 
Absorption of Oral Doses 
Blood level data were obtained for 44 patients 
after oral administration of MTX, based on 102 
doses of MTX. Most of these patients were exposed 
to MTX for the first time and none had received 
the drug in the previous 3 months. Oral absorption 
as indicated by serum levels was often rapid but, as 
with clearance of intravenous and intramuscular 
doses, much variation was seen. Figure 7 shows the 
great variations in serum levels in the first 24 hr 
after single oral doses of 0.22 mg/kilo. 
An attempt was made to correlate pooled serum 
level data as shown in Figure 7 with overall clinical 
response to treatment. Figure 8 shows the serum 
MTX levels for a number of patients with compa-
rable patterns of psoriasis who were given 0.22 
mg/kilo doses. The data are divided according to 
whether clinical response was "good" or "poor." It 
can be seen that there are no significant differences 
between the levels at various intervals after the 
dose in the two "response groups." 
Interpatient Variation (Oral Doses) 
Three fairly distinct patterns of blood levels and 
a mixed group were seen after single oral doses of 
MTX, and these have been arbitrarily delineated 
as follows. Types I and II are naturally exclusive 
but Type III overlapped with both . 
Type I-Rapid Absorption Leading to High Levels 
and Rapid Fall 
Criteria: 125 nglml or more at 30 min 
500 nglm! or more at 1 hr 
1000 nglml or more at 2 hr 
500 nglml or less at 4 hr 
Figure 9 shows three examples of this pattern of 
response. The details of clinical response and 
toxicity are shown in Table L Throughout the 
period of treatment not one of these patients 
exhibited serious clinical or laboratory evidence of 
toxicity. Four patients complained of mild ano-
rexia and nausea, lasting 12 to 36 hr and usually 
beginning about 18 hr after each dose. One (the 
patient who failed to respond) suffered abdominal 
pain. Mter 0.44 mg/kg doses, 7 patients showed 
this blood level pattern, including 3 who had 
responded similarly to 0.22 mg/kilo doses. Of these 
7, 3 responded very well and 3 moderately well to 
treatment. Only 1 patient failed to improve. 
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FIG. 9. Type I response to oral methotrexate. showing 
high peak levels and rapid fall. 
T ABLE I. Patterns of methotrexate blood levels, clinical 
response, and toxicity after oral doses of 0.22 mglkila 
Response Toxicity 
No.of 
patients Very Mod· Poor Seri~ good erate ous 
Type I 
Rapid rise and 12 5 6 1 0 
fall 
Type II 
Low rise and 11 3 3 5 0 
low peak 
Type III 
Delayed fall 9 4 3 2 0 
Type II-"Slow Rise and Low Peak" Curues 
Criteria: 64 ng/ml or less at 30 min 
125 ng/ml or less at 1 hr 
250 ng/ml or less at 2 hr 
Mild 
4 
6 
0 
Figure 10 shows three examples of this pattern of 
response. Two of the patients who failed to respond 
(both with erythrodermic psoriasis) had exception-
ally low blood levels and it seems possible that 
their lack of response was due to low absorption. 
One patient had previously responded well to 
parenteral therapy, supporting this contention. At 
first it was suspected that he had not in fact taken 
the MTX tablets, but repeated administration 
(when the tablets were swallowed under supervi-
sion) gave the same results. 
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Type III-Delayed Fall in Blood Levels 
Criteria: 100 ng/ml or more at 12 hr 
16 ng/ml or more at 24 hr 
8 ng/ml or more at 48 hr 
After 0.22 mg/kilo doses, 9 patients showed 
delayed fall, including 4 who had high initial peaks 
and 4 with low peak curves (Table I). After 0.44 
mg/kilo doses, 12- to 48-hr levels were higher and 5 
of 12 subjects given doses of this order showed such 
levels; 3 of these latter patients had a good 
response and the other 2 a moderate response. 
Mixed patterns. Nineteen patients did not fit 
any of the above categories and showed various 
mixed patterns of response. 
Comparison of Oral Absorption Tests Before and 
After Prolonged Therapy 
Five patients with a Type I absorption pattern, 
whose psoriasis was well controlled by MTX, had 
oral absorption studies repeated after 6 to 18 
months of continuous treatment with the drug. No 
alteration in their absorption pattern was seen. 
One other patient, originally studied in a phase of 
widespread discoid psoriasis, showed a flatter ab-
sorption curve during an acute phase of erythro-
dermic psoriasis when her psoriasis was out of con-
trol at a later date (after a period without MTX)_ 
This may have been a reflection of an acute "der-
matogenic enteropathy." 
Relationship o[ Serum MTX and Albumin Levels 
Sixteen patients had serum albumin levels 
greater than 4.2 gm% at the time of MTX serum 
level studies. Ten responded very well, and 4 
moderately well to treatment. Only 2 of these 
patients were receiving salicylate or sulfonamides 
at the same time, which might have competed for 
albumin-binding sites. Four patients, all with 
1000 
100 
S.,um 
Methot".m lng/mil 
10 
H!'$ afler dose 
FIG. 10. Type II response to oral methotrexate. show-
ing slow rise and low peak_ 
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erythrodermic or generalized pustular disease, had 
serum albumin levels of 3.0 gm % or less at the time 
of study. All 3 responded excellently to repeated 
doses of 0.22 mg/kilo, orally or parenterally, and 
had Type I serum level patterns. 
Relationship of Serum MTX Levels to Renal 
Function 
In patients with a renal creatinine clearance 
greater than 50 ml/min no correlation was observed 
between serum MTX levels (peak or duration) and 
the creatinine clearance. In 4 patients with poor 
renal function, slow excretion of the drug was 
clearly related to low creatinine clearance and 
dosage was adjusted accordingly. One 83-year-old 
man with intractable and disabling, widespread 
discoid psoriasis, whose creatinine clearance was 
23 mVmin, was kept well controlled for over a year 
by 2.5 mg MTX by mouth weekly. after a test 
dose had suggested delayed excretion. Six- and 
twelve-hour serum MTX measurements after a 
small intravenous test dose provide a useful guide 
to subsequent therapy in patients with kidney 
disease whose psoriasis cannot be managed by 
topical measures. We have detected no evidence 
that such treatment itself causes further renal 
damage. 
Relationship of Red-Cell Levels of MTX and 
Clinical Response and Taxicity 
The assay system demonstrated that MTX is 
taken up by red cells, peak levels reflecting peak 
serum levels. After 0.22 mglkilo doses, many 
patients achieved peak red-cell levels of 32 ng/ml 
RCL or greater. In most of these subjects the level 
had fallen to zero after 24 hr. However, a number of 
patients failed to show peak levels greater than 4 
ng/ml RCL. Contrasting groups of patients with 
peak erythrocyte levels greater than 32 and less 
than 4 have been compared in respect to clinical 
response of psoriasis and toxicity (Tab. II). Of 15 
patients with the high peak levels, 10 responded 
well and only 1 failed to improve significantly. Of 
10 patients with peak levels of 4 or less, 4 patients 
were completely resistant to therapy which was 
later abandoned (see Tab. II). Five patients had 
persistent erythrocyte levels of 4 ng/ml RCL or 
more 24 hr after single doses of 0.22 mg/kilo; all 
responded very well clinically. Four of the 5 are on 
successful long-term maintenance treatment. No 
TABLE II. Relationships of peak red-cell lysate 
methotrexate levels to clinical response and toxicity 
Red·celllysate No. Very Moder- Nore- Tox-arpa· good reo ate re-(ng/mll tients sponse sponse sponse icity 
High peak levels (~32) 15 10 4 1 5 
Low peak levels (';!!4) 10 5 1 4 7 
High persistent levels 5 5 0 0 1 
(~4 at 24 hr) 
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relationship was apparent between erythrocyte 
MTX levels and incidence or type of toxicity. 
DISCUSSION 
Laboratory Studies 
A variety of results was obtained from the 
urinary excretion studies, some patients appar· 
ently excreting much and others little of the drug 
by this route. These results may be compared with 
those of Johns et al [8] who, in 4 subjects, found 
the excretion of tritium-labeled MTX to range 
from 38 to 57% of the intravenously administered 
dose in the first 48 hr. After 48 hr the substances 
excreted by this route were metabolites rather than 
unchanged MTX. Johns and his colleagues found 
that further labeled material could be flushed from 
the tissues by compounds which competed for the 
enzyme dihydrofolate reductase; clearly some tis· 
sue binding occurs. The extent of this binding is 
difficult to assess for Johns and his co-workers took 
no account of excretion via the bile, although 
acknowledging that such excretion may occur. We 
have demonstrated biliary excretion in patients 
receiving parenteral doses. Henderson et al [5 J 
found that, in 10 cancer patients, from 54 to 88% of 
a small intravenous or oral dose of MTX was 
excreted via the urine within the first 24 hr, and 
that from 4 to 24% appeared in subsequent urines 
or in the stool. Some of the patients in the present 
series of experiments excreted significantly less 
even than the 38% reported by Johns et aI, but it is 
important to note that the microbiologic method 
measures an active folic acid antagonist. It may be 
speculated that some MTX is inactivated in the 
body and thus not detected in this assay. Very high 
recovery rates from some patients, however, sug-
gest that this phenomenon may be expressed only 
in some individuals. No other studies on patients 
without cancer appear to be available_ 
Henderson et al [5] reported that a bout 50% of 
MTX is bound to serum proteins. It was not 
possible to demonstrate such binding in the pres-
ent study. In vitro addition of MTX to distilled 
water, normal urine, and horse serum revealed no 
differences in fluid levels of MTX on assay. Auto· 
claving had no significant effect on the levels 
assayed in serum from patients treated with the 
drug (although this releases folic acid [7]). 
Clinical Studies 
Our studies established that variations in activ· 
ity of tbe different commercial batches of inject-
able and tablet forms of MTX available to us were 
small and could not contribute significantly to the 
variations in clinical response and toxicity ob-
served. 
Considerable variation has been found in the 
measured blood levels after standard oral and 
parenteral MTX administration. These presum-
ably reflect variations in the balance between rate 
and extent of absorption from the gut, rates of 
excretion by the kidneys and the liver, and uptake 
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and release of the drug by the tissues. Hepatic 
excretion is itself complicated by the existence of 
an enterohepatic cycling of MTX. The fact that we 
have observed just as much variation in blood 
levels after parenteral administration suggests that 
variation in absorption is the least important of 
these factors. This is consistent with the observa-
tion of Halprin et al [9] in a small number of pa-
tients that there was a direct relationship between 
the amount of MTX administered orally and the 
blood levels achieved 2 hr later. Nevertheless, 
there may be occasional patients, especially those 
with psoriatic erythroderma, who do not absorb 
MTX normally, although we cannot prove that 
their low blood levels were not due to avid and ex-
ceptional uptake by the dihydrofolate reductase of 
the erythrodermic skin. 
Our assay is thought to measure total free and 
protein-bound MTX in the blood, but it is a matter 
of conjecture how these levels are related to the 
intracellular levels in skin and other organs, on 
which therapeutic benefit and toxicity must de-
pend. Our inability to correlate our assay data with 
clinical response or toxicity (see Fig. 8) confirms 
that serum levels are a crude indicator of drug 
metabolism and of little value except in gross 
situations such as renal disease. However, the data 
in Table II suggest that red-cell level measurement 
may be a better parameter. 
Much work in the last two decades has led to the 
realization that the distribution of MTX in the 
body depends on multiple and complex factors. 
Renal function must be of prime importance in 
view of the evidence that much of an administered 
dose is eventually excreted by this organ [5] 
Hepatic function is concerned at the levels of the 
extent of biliary secretion, enterohepatic cycling, 
and cellular function. At the terminal level, the 
cellular reproductive activity of the skin, the ex-
tent and type of the psoriasis, the skin's blood 
supply, and the cellular levels of dihydrofolate 
reductase must be important-similar considera-
tions applying to other organs where toxicity may 
prejudice continued therapy. Tissue levels of fo-
lates, particularly in the liver, may be important; 
this aspect is complicated by the recent observa-
tion that MTX increased the renal excretion of 
folate [lO). 
Routine control of MTX therapy in psoriasis by 
measurement of blood levels of the drug may not 
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be worthwhile. The microbiologic assay is too 
tedious and time consuming although accurate and 
reproducible. Although results can be available 
within 36 hr, clinical manifestations of toxicity 
may appear earlier. Blood levels can be valuable, 
however, in three clinical situations: 
1. Where severe psoriasis is associated with 
severe renal disease. Blood levels following a very 
small intravenous test dose provide a guide to the 
appropriate dosage. Our limited experience pro-
vides no evidence that small maintenance doses 
further aggravated renal function. 
2. Where psoriasis is apparently refractory to 
oral dosage and parenteral therapy is difficult or 
impossible. Blood studies distinguish between fail-
ure of absorption and refractoriness for other 
(unknown) reasons. 
3. To confirm that the tablets are being taken as 
prescribed. 
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